Cargando…

Augmented Renal Clearance: What Have We Known and What Will We Do?

Augmented renal clearance (ARC) is a phenomenon of increased renal function in patients with risk factors. Sub-therapeutic drug concentrations and antibacterial exposure in ARC patients are the main reasons for clinical treatment failure. Decades of increased research have focused on these phenomena...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Yifan, Wang, Yidan, Ma, Yue, Wang, Puxiu, Zhong, Jian, Chu, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593401/ https://www.ncbi.nlm.nih.gov/pubmed/34795579 http://dx.doi.org/10.3389/fphar.2021.723731

Ejemplares similares

Drugs for malaria elimination: what do we have now and what do we need?
por: Shanks, Dennis
Publicado: (2014)

Pharmacological Intervention to Modulate HDL: What Do We Target?
por: Woudberg, Nicholas J., et al.
Publicado: (2018)

Cardiovascular imaging: what have we learned from animal models?
por: Santos, Arnoldo, et al.
Publicado: (2015)

INDIAN PSYCHIATRY AT THE CROSSROADS - WHAT WE CAN DO WITH WHAT WE HAVE?1
por: Channabasavanna, S.M.
Publicado: (1992)

What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?
por: Lacroix, Clémence, et al.
Publicado: (2022)

Time-restricted feeding: what we have done and what more we can do?
por: Sun, Yuning, et al.
Publicado: (2023)

Contextualising the Perceptions of Pharmacists Practicing Clinical Pharmacy in South Africa—Do We Practice what We Preach?
por: Bronkhorst, Elmien, et al.
Publicado: (2021)

PTH Assays: Understanding What We Have and Forecasting What We Will Have
por: Vieira, Jose Gilberto H.
Publicado: (2012)

Multimorbidity: What do we know? What should we do?
por: Navickas, Rokas, et al.
Publicado: (2016)

Implementation of HPV Tests in Latin America: What We Learned; What Should We Have Learned, and What Can We Do Better?
por: Godoy, Luani Rezende, et al.
Publicado: (2022)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

What have we learned and what do we still need to learn about nPDF?
por: Paakkinen, Petja
Publicado: (2021)

Acute severe hepatitis outbreak in children: A perfect storm. What do we know, and what questions remain?
por: Matthews, Philippa C., et al.
Publicado: (2022)

SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses
por: Fiorino, Sirio, et al.
Publicado: (2022)

Particle Physics Outreach: What we are doing and what we could be doing
por: Goldfarb, Steven
Publicado: (2018)

COVID-19 vaccine: what are we doing and what should we do?
por: Candelli, Marcello
Publicado: (2022)

Presbyopia: What We Do Know and What We Do Not Know in 2022
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

Keeping the Journal in the Second Quarter: What Are We Doing and What Will We Do?
por: Altay, Servet
Publicado: (2023)

Retinal Glaucoma Public Datasets: What Do We Have and What Is Missing?
por: Camara, José, et al.
Publicado: (2022)

Population Equation: Balancing What We Need With What We Have
por: Dahl, Richard
Publicado: (2005)

Reversal Agents: What We Have and What We Can Expect
por: Ruff, Christian T.
Publicado: (2018)

Artificial Intelligence in Urooncology: What We Have and What We Expect
por: Froń, Anita, et al.
Publicado: (2023)

AB132. Nocturnal penile tumescence monitoring: what have we done and what should we do?
por: Gao, Liang, et al.
Publicado: (2015)

One year after the COVID-19: What have we learnt, what shall we do next?
por: Gorwood, Philip, et al.
Publicado: (2021)

China's Fight Against COVID-19: What We Have Done and What We Should Do Next?
por: Cheng, Sixiang, et al.
Publicado: (2022)

Mixed Neuroendocrine and Non-Neuroendocrine Neoplasm of Pancreas: What Do We Know, What Have We Learnt?
por: Dhakre, Vijay W., et al.
Publicado: (2023)

Neurologic Complications With Vaccines: What We Know, What We Don't, and What We Should Do
por: Nath, Avindra
Publicado: (2023)

Laryngopharyngeal reflux concept: what is known and what should we focus on?()
por: Sirin, Seher, et al.
Publicado: (2019)

Role of the Eye in Transmitting Human Coronavirus: What We Know and What We Do Not Know
por: Sun, Chuan-bin, et al.
Publicado: (2020)

What have we learned?
por: Rodgers, Peter, et al.
Publicado: (2021)

The risk of viral transmission in feed: What do we know, what do we do?
por: Dee, Scott A., et al.
Publicado: (2020)

Understanding the lingering consequences of what we treat and what we do
por: Angus, Derek C
Publicado: (2004)

What we see and what we do not see in health care
por: Škaričić, Nataša
Publicado: (2011)

Vaginal Aging—What We Know and What We Do Not Know
por: Szymański, Jacek K., et al.
Publicado: (2021)

Psychological Interventions for Dementia Caregivers: What We Have Achieved, What We Have Learned
por: Cheng, Sheung-Tak, et al.
Publicado: (2019)

Lipoabdominoplasty: What We Have Implemented and What We Have Modified over 26 Years
por: Cárdenas-Camarena, Lázaro, et al.
Publicado: (2023)

Do We Mean What We Say?
por: Towner, Ausburn
Publicado: (1885)

The cancer-obesity connection: what do we know and what can we do?
por: Riboli, Elio
Publicado: (2014)

Isolated Nocturnal Hypertension: What Do We Know and What Can We Do?
por: Tadic, Marijana, et al.
Publicado: (2020)

Multinational monkeypox outbreak: what do we know and what should we do?
por: Memariani, Mojtaba, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_egphihicesqg47t14d1etm9sre